SeaStar Medical is trading 10.97% higher at $3.54, with the FDA designation a possible catalyst. - On October 7, 2026, the FDA granted Breakthrough Device Designation to its SCD therapy for hyperinflammation in adults with sepsis or a septic condition; it may help accelerate development and FDA review. - Healthcare stocks were also higher, while major U.S. indexes were down. - Available sources do not establish trading volume or unusual activity.